Skip to main content

Table 1 Characteristics of t2t courses

From: Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg

   

Ineffective

 

Overall

No

Yes

P-Value

T2T courses (n)

 

1843

1724

119

 

BMI, mean (SD), (kg/m2)

 

26.4 (4.8)

26.5 (4.8)

26.4 (4.4)

0.830

Age, mean (SD), year

 

56.1 (13.6)

56.0 (13.6)

58.5 (13.5)

0.054

Gender, n (%)

M

407 (22.1)

380 (22.0)

27 (22.7)

0.960

F

1436 (77.9)

1344 (78.0)

92 (77.3)

 

Disease duration, mean (SD), year

 

10.4 (8.7)

10.4 (8.7)

11.4 (9.6)

0.257

IV administration, n (%)

No

1610 (87.4)

1507 (87.4)

103 (86.6)

0.897

Yes

233 (12.6)

217 (12.6)

16 (13.4)

 

MTX co-therapy, n (%)

No

824 (44.7)

766 (44.4)

58 (48.7)

0.413

Yes

1019 (55.3)

958 (55.6)

61 (51.3)

 

Other DMARD co-therapy, n (%)

No

1545 (83.8)

1454 (84.3)

91 (76.5)

0.033

Yes

298 (16.2)

270 (15.7)

28 (23.5)

 

GC co-therapy, n (%)

No

1156 (62.7)

1105 (64.1)

51 (42.9)

 < 0.001

Yes

687 (37.3)

619 (35.9)

68 (57.1)

 

Previous aTNF therapy, n (%)

No

1233 (66.9)

1168 (67.7)

65 (54.6)

0.004

Yes

610 (33.1)

556 (32.3)

54 (45.4)

 

HAQ, mean (SD)

 

1.0 (0.7)

1.0 (0.7)

1.2 (0.7)

0.015

Rheuma-factor-positivity, n (%)

No

480 (30.0)

443 (29.6)

37 (35.6)

0.241

Yes

1120 (70.0)

1053 (70.4)

67 (64.4)

 

VAS-Pat., mean (SD), mm

 

39.6 (24.4)

38.7 (24.2)

51.1 (24.6)

 < 0.001

VAS-Ph., mean (SD), mm

 

28.7 (20.1)

28.4 (20.1)

32.4 (20.4)

0.047

Anti-CCP, n (%)

No

409 (33.2)

380 (32.8)

29 (39.2)

0.317

Yes

823 (66.8)

778 (67.2)

45 (60.8)

 

TJC, mean (SD)

 

4.5 (4.7)

4.4 (4.6)

6.0 (5.8)

0.006

SJC, mean (SD)

 

3.0 (2.9)

2.9 (2.9)

3.6 (2.8)

0.020

CRP, mean (SD), mg/dL

 

8.9 (15.4)

8.6 (15.0)

11.9 (19.8)

0.102

ESR, mean (SD), mm/h

 

19.1 (17.9)

18.9 (17.7)

22.5 (20.8)

0.094

DAS28-ESR, mean (SD)

 

3.8 (1.5)

3.8 (1.5)

4.1 (1.5)

0.101

Smoker, n (%)

Current

161 (8.7)

151 (8.8)

10 (8.4)

0.978

 

Past

87 (4.7)

81 (4.7)

6 (5.0)

 
 

Never

1595 (86.5)

1492 (86.5)

103 (86.6)

 
  1. aTNF anti-tumor necrosis factor, CRP C-reactive protein, DAS28 Disease Activity Score 28, ESR erythrocyte sedimentation rate, TJC tender joint count, HAQ Health Assessment Questionnaire, SJC swollen joint count, VAS-Pat. visual analogue scale patient, VAS-Ph. visual analogue scale physician, Anti-CCP anti-cyclic citrullinated peptide, MTX methotrexate, IV Administration, intravenous administration, GC glucocorticoid
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us